Sacituzumab govitecan clinical trials
Also written Trodelvy, IMMU-132 and GS-0132.
ClinicalTrials.gov finds 172 studies for sacituzumab govitecan. How that becomes 102 here
Every study that search finds has been read, to see whether and how it gives sacituzumab govitecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 172Found by its intervention search · See all 172 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 140 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −7
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerNCT04916002 · Earlier treatment, not given in this studyReport a problem
- Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsNCT05126433 · Earlier treatment, not given in this studyReport a problem
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid TumorsNCT05438329 · Earlier treatment, not given in this studyReport a problem
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor MalignanciesNCT05627960 · Advice on earlier treatment; not given in this studyReport a problem
- The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard TherapyNCT07077564 · Written for sacituzumab tirumotecan, a different ADCReport a problem
- Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLCNCT07438600 · Written for sacituzumab tirumotecan, a different ADCReport a problem
- Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerNCT07811752 · Written for sacituzumab tirumotecan, a different ADCReport a problem
- 165Give sacituzumab govitecan to participants
- −17Observe patients on it, or give it outside a trial
- −3Use it as a tool: an imaging tracer or a test of drug response
- −6Compare another treatment with it
- −37Give it beside what is tested
- 102Test it: the count on this site
Get an email when these change. Save the sacituzumab govitecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Apr 2020 · TRODELVY · BLA 761115 (FDA, Drugs@FDA)
- European Union
- 22 Nov 2021 · Trodelvy · EMEA/H/C/005182 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
102 studies that test it; most in 2024 (25)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 13 |
| 2024 | 25 |
| 2025 | 15 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 72
Gilead Sciences (23) · National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (3) · Yale University (3) · Hoffmann-La Roche (3) · Massachusetts General Hospital (2) · SWOG Cancer Research Network (2) · University of Kansas Medical Center (2)
Often tested with
Tested in the same studies.
Pembrolizumab (6) · Zimberelimab (5) · Trastuzumab deruxtecan (5) · Enfortumab vedotin (5) · Atezolizumab (4) · Domvanalimab (3) · Carboplatin (3) · Nivolumab (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Sacituzumab govitecan is the comparator. A study of two new drugs counts under both.
- 1Eribulin · National Cancer Institute (NCI)
- 1Gemcitabine · National Cancer Institute (NCI)
- 1Apatinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Mar 2031
- 1Beruzatatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · next primary completion Dec 2027
- 1JSKN016 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · next primary completion Mar 2029
New treatments tested with it · 8 most studied
New when their studies opened, with sacituzumab govitecan beside them; studies of each.
- 2Zimberelimab
- 1Tuvutromstat
- 1Zedoresertib
- 1Berzosertib
- 1Azerutamig
- 1AB928
- 1Mocaciclib
- 1PARP1 Inhibitor GS-0201
Reaching primary completion within a year · 41, 5 in phase 3
Studies that test sacituzumab govitecan, phase 3 first.
- Dec 2026Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Phase 3 · Gilead Sciences
- Jan 2027Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Phase 3 · Merck Sharp & Dohme LLC
- Feb 2027Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerPhase 3 · Gilead Sciences
- Mar 2027Sacituzumab Govitecan in Primary HER2-negative Breast CancerPhase 3 · GBG Forschungs GmbH
- Jun 2027Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3 · Gilead Sciences
- Nov 2026Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaPhase 2 · National Taiwan University Hospital
- Nov 2026A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsPhase 2 · Yale University
- Nov 2026Sacituzumab Govitecan and Bevacizumab for NSCLC Brain MetastasesPhase 2 · Maastricht University Medical Center
- Dec 2026A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial CarcinomaPhase 2 · Yale University
- Dec 2026A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsPhase 1 · Hunan Cancer Hospital
Studies
Open first, then newest update. How each study uses sacituzumab govitecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 102
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544With pembrolizumab against standard chemotherapyWritten as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588With bevacizumab against chemotherapyWritten as Sacituzumab GovitecanReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Added to atezolizumab in one platform armWritten as Sacituzumab GovitecanReport a problem
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingPhase 3Gilead SciencesNCT05633654With pembrolizumab after surgery (ASCENT-05)Written as Sacituzumab govitecan-hziy (SG)Report a problem
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingPhase 3Gilead SciencesNCT06801834Against standard care in small cell lung cancerWritten as Sacituzumab Govitecan (SG)Report a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214One biomarker-directed ADC (ADC MATCH)Written as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...RecruitingPhase 2National Cancer Institute (NCI)NCT06161532Alone or with atezolizumab in rare genitourinary tumoursWritten as Sacituzumab govitecanReport a problem
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT07393555Alone or with ivonescimab after targeted therapy (Lung-MAP)Written as Sacituzumab GovitecanReport a problem
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingPhase 2Nathalie LevasseurNCT07299409First line in triple-negative breast cancerWritten as Sacituzumab Govitecan (SG)Report a problem
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2National Taiwan University HospitalNCT06329869In oesophageal squamous cell carcinomaWritten as Sacituzumab govitecanReport a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753One protein-matched ADCWritten as Sacituzumab govitecan (SG)Report a problem
- Sacituzumab govitEcan in THYroid CancersRecruitingPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT06235216In thyroid cancersWritten as Sacituzumab govitecanReport a problem
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingPhase 2Georgetown UniversityNCT06248515In thymic epithelial tumoursWritten as Sacituzumab govitecan-hziyReport a problem
- Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerRecruitingPhase 1/2Icahn School of Medicine at Mount SinaiNCT06040970With cisplatin in platinum-sensitive gynaecological cancersReport a problem
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCRecruitingPhase 2Reshma L. Mahtani, D.O.NCT06263543Sequenced with another ADC in HER2-low breast cancerWritten as Sacituzumab govitecanReport a problem
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingPhase 3Women's Cancer Study Group GmbHNCT07178730With pembrolizumab before surgery against chemotherapyWritten as Sacituzumab govitecanReport a problem
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Bindu R PotugariNCT07339059With atezolizumab or durvalumab as maintenanceWritten as Sacituzumab govitecanReport a problem
- A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerRecruitingPhase 2Yale UniversityNCT05838521In recurrent cervical cancerWritten as Sacituzumab govitecanReport a problem
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder CancerRecruitingPhase 1Shilpa Gupta, MDNCT05833867With adaptive radiotherapy in bladder cancerWritten as Sacituzumab govitecanReport a problem
- Sacituzumab Govitecan In TNBCRecruitingPhase 2Massachusetts General HospitalNCT04230109Alone or with pembrolizumab before surgeryWritten as Sacituzumab GovitecanReport a problem
See all 102 studies that test sacituzumab govitecan →
Behind its US label · 5 — the studies the FDA label of TRODELVY describes
From the Clinical Studies section of TRODELVY (2026-06), as openFDA has it. A study the site does not hold is left out.
- Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedPhase 1/2Gilead SciencesNCT01631552Report a problem
- Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedPhase 3Gilead SciencesNCT02574455Report a problem
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerCompletedPhase 3Gilead SciencesNCT03901339Report a problem
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 3Gilead SciencesNCT05382286Report a problem
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 3Gilead SciencesNCT05382299Report a problem
Tested on its own · 43 — no other medicine in its arm
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingPhase 2Nathalie LevasseurNCT07299409First line in triple-negative breast cancerWritten as Sacituzumab Govitecan (SG)Report a problem
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2National Taiwan University HospitalNCT06329869In oesophageal squamous cell carcinomaWritten as Sacituzumab govitecanReport a problem
- Sacituzumab govitEcan in THYroid CancersRecruitingPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT06235216In thyroid cancersWritten as Sacituzumab govitecanReport a problem
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingPhase 2Georgetown UniversityNCT06248515In thymic epithelial tumoursWritten as Sacituzumab govitecan-hziyReport a problem
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCRecruitingPhase 2Reshma L. Mahtani, D.O.NCT06263543Sequenced with another ADC in HER2-low breast cancerWritten as Sacituzumab govitecanReport a problem
- A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerRecruitingPhase 2Yale UniversityNCT05838521In recurrent cervical cancerWritten as Sacituzumab govitecanReport a problem
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder CancerRecruitingPhase 1Shilpa Gupta, MDNCT05833867With adaptive radiotherapy in bladder cancerWritten as Sacituzumab govitecanReport a problem
- Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT05770531Switched to on ctDNA rise in triple-negative diseaseWritten as Sacituzumab GovitecanReport a problem
- Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentRecruitingPhase 1Gilead SciencesNCT04617522In moderate liver impairmentWritten as Sacituzumab Govitecan-hziyReport a problem
- A Study of Sacituzumab Govitecan in People With MesotheliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06477419In mesotheliomaWritten as Sacituzumab govitecan-hziyReport a problem
- Sacituzumab Govitecan in Recurrent GlioblastomaRecruitingPhase 2The University of Texas Health Science Center at San AntonioNCT04559230In recurrent glioblastomaWritten as Sacituzumab GovitecanReport a problem
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingPhase 1/2Gilead SciencesNCT06926920At an alternative dose and scheduleWritten as Sacituzumab Govitecan-hziy (SG)Report a problem
- Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)RecruitingPhase 2National University Hospital, SingaporeNCT06923826In salivary gland and thyroid cancersWritten as Sacituzumab govitecanReport a problem
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerRecruitingPhase 2British Columbia Cancer AgencyNCT06665178After trastuzumab deruxtecan, sensitivity predictors studiedWritten as Sacituzumab GovitecanReport a problem
- HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab GovitecanRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT06236269In HR-positive breast cancer, single armWritten as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan in Metastatic Colorectal CancerRecruitingPhase 2/3University Hospital HeidelbergNCT06243393Against physician's choice in colorectal cancerWritten as Sacituzumab Govitecan (SG)Report a problem
- Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain MetastasesNot yet recruitingPhase 2Guangzhou Medical UniversityNCT06462079With brain radiotherapy in breast cancerWritten as Sacituzumab GovitecanReport a problem
- Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05884320In secretory gland cancersWritten as Sacituzumab GovitecanReport a problem
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)Active, not recruitingPhase 3Gilead SciencesNCT06486441Against chemotherapy in endometrial cancer (ASCENT-GYN-01)Written as Sacituzumab govitecan-hziyReport a problem
- Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast CancerActive, not recruitingPhase 3UNICANCERNCT05552001In triple-negative breast cancerWritten as Sacituzumab govitecanReport a problem
Showing 20 of 43. See all 43 →
Tested with established drugs · 13 — they are given beside it
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588With bevacizumab against chemotherapyWritten as Sacituzumab GovitecanReport a problem
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingPhase 3Gilead SciencesNCT05633654With pembrolizumab after surgery (ASCENT-05)Written as Sacituzumab govitecan-hziy (SG)Report a problem
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingPhase 3Women's Cancer Study Group GmbHNCT07178730With pembrolizumab before surgery against chemotherapyWritten as Sacituzumab govitecanReport a problem
- Sacituzumab Govitecan In TNBCRecruitingPhase 2Massachusetts General HospitalNCT04230109Alone or with pembrolizumab before surgeryWritten as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast CancerRecruitingPhase 1/2Guangzhou Medical UniversityNCT06462092With intrathecal pemetrexed for leptomeningeal metastasesWritten as Sacituzumab GovitecanReport a problem
- A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07040644With toripalimab against nab-paclitaxelWritten as Sacituzumab Govitecan (SG)Report a problem
- Sacituzumab Govitecan and Bevacizumab for NSCLC Brain MetastasesRecruitingPhase 2Maastricht University Medical CenterNCT06401824With bevacizumab in lung cancer brain metastasesWritten as Sacituzumab Govitecan-Hziy 180 MG plus bevacizumabReport a problem
- Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Gilead SciencesNCT05186974With pembrolizumab or platinum first line in lung cancer (EVOKE-02)Written as Sacituzumab Govitecan-hziy (SG)Report a problem
- Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.Active, not recruitingPhase 1/2Massachusetts General HospitalNCT04039230With talazoparib in triple-negative breast cancerWritten as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasTerminatedPhase 2National Cancer Institute (NCI)NCT06865677In relapsed ovarian, endometrial and cervical cancersWritten as Sacituzumab GovitecanReport a problem
- Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05609968Added to pembrolizumab in lung cancer (EVOKE-03)Written as Sacituzumab GovitecanReport a problem
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 3Gilead SciencesNCT05382286On the US labelWith pembrolizumab against chemotherapy (ASCENT-04)Written as Sacituzumab Govitecan-hziyReport a problem
- Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerWithdrawnPhase 2Gilead SciencesNCT02161679Alone or with carboplatin in triple-negative breast cancerWritten as IMMU-132 infusion is administered to participants in one arm for the studyReport a problem
Tested in a combination · 46 — another drug in the study is under test too
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544With pembrolizumab against standard chemotherapyWritten as Sacituzumab GovitecanReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Added to atezolizumab in one platform armWritten as Sacituzumab GovitecanReport a problem
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingPhase 3Gilead SciencesNCT06801834Against standard care in small cell lung cancerWritten as Sacituzumab Govitecan (SG)Report a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214One biomarker-directed ADC (ADC MATCH)Written as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...RecruitingPhase 2National Cancer Institute (NCI)NCT06161532Alone or with atezolizumab in rare genitourinary tumoursWritten as Sacituzumab govitecanReport a problem
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT07393555Alone or with ivonescimab after targeted therapy (Lung-MAP)Written as Sacituzumab GovitecanReport a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753One protein-matched ADCWritten as Sacituzumab govitecan (SG)Report a problem
- Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerRecruitingPhase 1/2Icahn School of Medicine at Mount SinaiNCT06040970With cisplatin in platinum-sensitive gynaecological cancersReport a problem
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Bindu R PotugariNCT07339059With atezolizumab or durvalumab as maintenanceWritten as Sacituzumab govitecanReport a problem
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07011654With naxitamab in triple-negative breast cancerWritten as Sacituzumab govitecanReport a problem
- IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian CancerNot yet recruitingPhase 1Shanghai Gynecologic Oncology GroupNCT07674615Alone in TROP2-high ovarian cancerReport a problem
- Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingPhase 3Fundación GECPNCT06431633With new zimberelimab against chemotherapy in lung cancerWritten as Sacituzumab govitecanReport a problem
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2West China HospitalNCT07492914With new tagitanlimab before head and neck surgeryWritten as Sacituzumab GovitecanReport a problem
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Alone in one platform substudyWritten as Sacituzumab govitecanReport a problem
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingPhase 2Dana-Farber Cancer InstituteNCT04434040With atezolizumab after treatment of triple-negative disease (ASPRIA)Written as Sacituzumab govitecanReport a problem
- Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingPhase 2University of California, IrvineNCT06682728With nivolumab after bladder cancer surgeryWritten as Sacituzumab Govitecan (SG)Report a problem
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07063212With cetuximab in head and neck cancerWritten as Sacituzumab GovitecanReport a problem
- Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07368543Sequenced with trastuzumab deruxtecan, order comparedWritten as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCEnrolling by invitationPhase 2YING FANNCT07359404With bevacizumab in triple-negative breast cancerWritten as Sacituzumab Govitecan (SG)Report a problem
- Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyRecruitingPhase 1Henry Ford Health SystemNCT06065371With capecitabine in gastrointestinal cancersWritten as Sacituzumab goveticanReport a problem
Showing 20 of 46. See all 46 →
Beside an established treatment under test · 6 — an approved drug, surgery or radiation is what the study tests
Tested with sacituzumab govitecan: pembrolizumab 3 · Nivolumab 1 · Hydroxychloroquine 1
- Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingPhase 2UNICANCERNCT07151586In every armBoth arms take it; alternating with trastuzumab deruxtecan is testedWritten as Sacituzumab Govitecan / Trastuzumab DeruxtecanReport a problem
- NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)RecruitingPhase 3Women's Cancer Study Group GmbHNCT06081244In every armEvery arm takes it while pembrolizumab is added before surgeryWritten as Sacituzumab govitecanReport a problem
- Saci Nivo Rela for TNBCRecruitingPhase 1/2Yale UniversityNCT06963905In every armEvery arm takes it while nivolumab, with or without relatlimab, is addedWritten as Sacituzumab Govitecan (SG)Report a problem
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingPhase 2Dana-Farber Cancer InstituteNCT04468061In every armEvery arm takes it while pembrolizumab is addedWritten as Sacituzumab GovitecanReport a problem
- HCQ+ADC vs ADC in the Treatment of Advanced Breast CancerRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06328387Both arms take it while hydroxychloroquine is addedWritten as Sacituzumab GovitecanReport a problem
- Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCActive, not recruitingPhase 2Ana C Garrido-Castro, MDNCT04448886In every armEvery arm takes it while pembrolizumab is addedWritten as Sacituzumab GovitecanReport a problem
Beside a new treatment under test · 14 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with sacituzumab govitecan: zimberelimab 2 · tuvutromstat 1 · zedoresertib 1 · berzosertib 1 · azerutamig 1 · AB928 1 · mocaciclib 1 · PARP1 Inhibitor GS-0201 1
- Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsRecruitingPhase 1Gilead SciencesNCT06167317Partner of new GS-0201 in one armWritten as Sacituzumab GovitecanReport a problem
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Partner of new AVZO-021 in one armWritten as Sacituzumab Govitecan-hziyReport a problem
- Sacituzumab Govitecan and Q901 in Advanced TNBCNot yet recruitingPhase 2Yonsei UniversityNCT07788222In every armPartner of new Q901Written as Sacituzumab govitecan and Q901Report a problem
- Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT06238921In every armPartner of new zimberelimab with radiosurgeryWritten as Sacituzumab govitecanReport a problem
- A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid TumorsRecruitingPhase 1/2Marengo Therapeutics, Inc.NCT06827613In every armPartner of new invikafusp alfa in one armWritten as Sacituzumab Govitecan (SG)Report a problem
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsCompletedPhase 1/2National Cancer Institute (NCI)NCT04826341In every armPartner of new berzosertibWritten as Sacituzumab GovitecanReport a problem
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid MalignanciesTerminatedPhase 1Gilead SciencesNCT05006794Partner of new zamzetoclax in one armWritten as sacituzumab govitecan-hziyReport a problem
- Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnPhase 2MedSIRNCT07134556In every armPartner of new zimberelimab and domvanalimab, first lineWritten as Sacituzumab Govitecan (SG)Report a problem
- Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionActive, not recruitingPhase 1IDEAYA BiosciencesNCT04794699Partner of new IDE397 in one armWritten as Sacituzumab govitecanReport a problem
- Study of DF1001 in Patients With Advanced Solid TumorsCompletedPhase 1/2Dragonfly TherapeuticsNCT04143711Partner of new DF1001 in one armWritten as Sacituzumab Govitecan-hziyReport a problem
- Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast CancerActive, not recruitingPhase 1/2MedSIRNCT06612203In every armPartner of new Debio 0123Written as Debio 0123 and Sacituzumab govitecanReport a problem
- Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTerminatedPhase 2Gilead SciencesNCT04958785Partner of new magrolimab in one cohortWritten as Sacituzumab Govitecan-hziyReport a problem
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedPhase 1/2Arcus Biosciences, Inc.NCT04381832Partner of new etrumadenant in one armWritten as SGReport a problem
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedPhase 1/2ImmunityBio, Inc.NCT04927884In every armPartner of new N-803 combinationsWritten as Sacituzumab Govitecan-HziyReport a problem
Beside supportive care · 9 — a supportive treatment or test is studied
- SCALp Cooling for pReventing aLopecia With nEw anTibody-drug ConjugatesRecruitingPhase 2Jules Bordet InstituteNCT07474558One ADC while scalp cooling against hair loss is testedReport a problem
- Scalp Cooling in MBCRecruitingPhase 2Dana-Farber Cancer InstituteNCT04986579Treatment while scalp cooling against hair loss is testedWritten as Sacituzumab govitecanReport a problem
- Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT07471776One ADC while TROP2 PET is testedReport a problem
- Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast CancerNot yet recruitingPhase 2MedSIRNCT07367178In every armTreatment while atropine is tested for tolerabilityWritten as Sacituzumab Govitecan (SG)Report a problem
- Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersRecruitingPhase 2UNICANCERNCT07259226Standard treatment while resistance samples are studiedReport a problem
- Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2Yeon Hee ParkNCT06616987In every armTreatment while pegfilgrastim prevents neutropeniaWritten as Sacituzumab Govitecan with pegfilgrastimReport a problem
- Trop-2 Targeted PET Probes in Advanced TNBCRecruitingNot applicablePeking University Cancer Hospital & InstituteNCT07046455In every armTreatment while TROP2 PET probes are testedWritten as Sacituzumab Govitecan (SG)Report a problem
- Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDCompletedPhase 2MedSIRNCT05520723In every armTreatment while prophylaxis for its side effects is testedWritten as Sacituzumab govitecanReport a problem
- Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedPhase 2G1 Therapeutics, Inc.NCT05113966In every armTreatment while trilaciclib is tested against its toxicityWritten as Sacituzumab Govitecan-hziyReport a problem
One option of several · 8 — a test or a strategy chooses among drugs
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967In every armSwitch option after progression; a new vaccine is testedWritten as Sacituzumab GovitecanReport a problem
- BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCRecruitingPhase 2Fudan UniversityNCT06793332In every armOne TROP2 ADC option beside ivonescimabReport a problem
- A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell CarcinomaNot yet recruitingPhase 2Shanghai East HospitalNCT07778368One TROP2 ADC option with toripalimab and cisplatinReport a problem
- A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.RecruitingPhase 2Fudan UniversityNCT06889610One systemic option beside ablationReport a problem
- Optimal Application Timing of ADC Drugs for Advanced Breast CancerRecruitingPhase 2Liaoning Cancer Hospital & InstituteNCT07657130One ADC option; when to give ADCs is comparedReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One TROP2 ADC option in salivary gland cancerReport a problem
- ctDNA-guided Treatment Decision-makingRecruitingPhase 2Fudan UniversityNCT07394218One ADC option; ivonescimab is added by ctDNAReport a problem
- Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal MetastasisRecruitingPhase 4Fudan UniversityNCT06230055One systemic option while intrathecal chemotherapy is testedReport a problem
As the comparator · 6 — what is tested is compared with sacituzumab govitecan
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454One physician's-choice option against new YL202Written as Sacituzumab govitecanReport a problem
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareRecruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07533123One physician's-choice option against new JSKN016Written as Sacituzumab Govitecan for InjectionReport a problem
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824One physician's-choice option against organoid-guided treatmentWritten as Sacituzumab govitecanReport a problem
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04579224One choice of standard chemotherapy against eribulinWritten as Sacituzumab GovitecanReport a problem
- Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast CancerActive, not recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07371910One physician's-choice option against fluzoparib and apatinibReport a problem
- P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .WithdrawnPhase 2Veru Inc.NCT05008510Alone as the comparator; new sabizabulin is addedWritten as Sacituzumab Govitecan-hziyReport a problem
Observed · 17 — patients on it are followed, or it is given outside a trial
- A Real World Study of Sacituzumab GovitecanRecruitingFudan UniversityNCT06966141Real-world outcomes in HER2-negative breast cancerReport a problem
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingHellenic Cooperative Oncology GroupNCT07066917Among ADCs, response and resistance observedReport a problem
- Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world StudyRecruitingRegina Elena Cancer InstituteNCT06240195Biomarkers of efficacy and tolerability, observedReport a problem
- Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsRecruitingGuangzhou Institute of Respiratory DiseaseNCT07610616Tested on lung cancer organoids in the laboratoryReport a problem
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseRecruitingFundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalNCT07582887Genetic variants and ADC toxicity, observedWritten as Sacituzumab GovitecanReport a problem
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingFudan UniversityNCT07551050Patient-reported outcomes in practiceReport a problem
- To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.RecruitingZhejiang Cancer HospitalNCT06784921Real-world use in HER2-negative breast cancerReport a problem
- Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World StudyRecruitingPeking University Cancer Hospital & InstituteNCT07251868In breast cancer brain metastases, observedWritten as Sacituzumab Govitecan (SG)Report a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingFondazione Policlinico Universitario Campus Bio-MedicoNCT07021911One treatment group in a radiotherapy studyReport a problem
- Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker ExplorationRecruitingPeking University Cancer Hospital & InstituteNCT06991790With toripalimab first line, observedWritten as Sacituzumab Govitecan (SG)+ToripalimabReport a problem
- Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast CancerRecruitingSun Yat-sen UniversityNCT06877416Among ADCs, treatment sequences observedReport a problem
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast CancerNot yet recruitingFudan UniversityNCT06798506Patient-reported outcomes in practiceReport a problem
- Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast CancerRecruitingFudan UniversityNCT06356519Real-world use in Chinese breast cancerWritten as Sacituzumab GovitecanReport a problem
- Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab GovitecanCompletedHellenic Cooperative Oncology GroupNCT06504719Real-world use beside trastuzumab deruxtecanReport a problem
- Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerActive, not recruitingPeking University Cancer Hospital & InstituteNCT07018427Real-world use alone or in combinationReport a problem
- Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related ToxicitiesCompletedCentral South UniversityNCT05349383Among ADCs, sepsis-related toxicity reportsReport a problem
- Expanded Access for IMMU-132Approved for marketingGilead SciencesNCT04320693Expanded accessWritten as IMMU-132Report a problem
As a tool · 3 — an imaging tracer or a test of drug response
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationEarly Phase 1Brigham and Women's HospitalNCT06204614Microdosed in an implanted drug-screening deviceReport a problem
- NIR Fluorescent Molecular Probe for the Identification of Breast TissueCompletedNot applicableXiang'an Hospital of Xiamen UniversityNCT05708144Labelled as a fluorescent probe on removed tissueReport a problem
- Implantable Microdevice for TNBC - Pilot StudyWithdrawnPhase 1Dana-Farber Cancer InstituteNCT05774886A microdose released by an implanted deviceReport a problem
Codes
What other systems call sacituzumab govitecan · ClinicalTrials.gg INT000470
- MeSH (NLM) C000608132sacituzumab govitecanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) M9BYU8XDQ6SACITUZUMAB GOVITECANConfirmed FDA, NLM, Wikidata
- RxNorm 2360232One source FDA
- Wikidata Q23901469sacituzumab govitecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102783Sacituzumab GovitecanOne source FDA
- DrugBank DB12893One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608132 | sacituzumab govitecan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | M9BYU8XDQ6 | SACITUZUMAB GOVITECAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2360232 | — | One source FDA |
| Wikidata | Q23901469 | sacituzumab govitecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102783 | Sacituzumab Govitecan | One source FDA |
| DrugBank | DB12893 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.